Navigation Links
Genzyme Reports Strong Second-Quarter Growth
Date:7/23/2008

metables therefore and the impact of such approvals on the company; its plans and estimated timetables for new and next- generation product filings, approvals and launches, including for Mozobil, Genz-112638, and Synvisc-ONE, its estimates of the sales potential of Clolar and Mozobil; its anticipated growth drivers for certain products and businesses, including Genetics; and its expectations for Renvela formulary access. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those forecasted. These risks and uncertainties include, among others: Genzyme's ability to obtain and maintain regulatory approvals for products and manufacturing facilities, including Myozyme produced at the 2000L scale in the US and at the 4000L scale in Europe and the timing of receipt of such approvals; Genzyme's ability to successfully complete preclinical and clinical development of its products and product candidates, including Mozobil and Genz-112638; Genzyme's ability to expand the use of current and next-generation products in existing and new indications, including Renvela, Clolar and Synvisc-ONE; Genzyme's ability to manufacture its products, including Thymoglobulin and its LSD therapies in a timely and cost effective manner and in sufficient quantities to meet demand; and the risks and uncertainties described in Genzyme's SEC reports filed under the Securities Exchange Act of 1934, including the factors discussed under the caption "Risk Factors" in Genzyme's 2008 Quarterly Report on Form 10-Q for the quarter ended March 31, 2008. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of today's date and Genzyme undertakes no obligation to update or revise the statements.

Genzyme(R), Myozyme(R), Fabrazyme(R), Cerezyme(R), Thyrogen(R), Renagel(R), Renvela(R), Thymoglobulin(R), Synvisc(R), Campath(R) and Clolar(R) are
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 BCC Research ( ... DIGITAL POLYMERASE CHAIN REACTION (PCR) TECHNOLOGY: GLOBAL MARKETS , ... technology reached nearly $140 billion in 2013. This is ... a five-year compound annual growth rate (CAGR) of 28.6%. ... of interesting and exciting possibilities within the broader PCR ...
(Date:7/10/2014)... Faso (PRWEB) July 10, 2014 ... today have access to an additional family planning ... access to contraception at all levels of the ... lower-dose formulation of a widely used contraceptive—Pfizer’s Depo-Provera® ... , Burkina Faso is the first of four ...
(Date:7/10/2014)... Francisco, CA (PRWEB) July 10, 2014 ... family closer together. The Archer Family purchased a ... contained within DNA, but ended up with a lifetime ... discoveries contained within the family members’ DNA genuinely brought ... had decided to search deeper into genetic history and ...
(Date:7/10/2014)... , July 10, 2014  Franciscan St. ... of capnography for respiratory monitoring outside the ... healthcare leaders in embracing state-of-the-art patient safety ... patients are breathing and can alert medical ... measuring the amount of carbon dioxide the ...
Breaking Biology Technology:Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2
... Grow to $10.5 Million in 2007; MOXATAG, Company,s Lead, PULSYS ... ... Alternatives Ongoing, GERMANTOWN, Md., March 4 ... focused on,developing and commercializing novel anti-infective products, today,announced financial and ...
... LAS VEGAS, March 4 ,Cord Blood America, Inc. ... cell preservation company ( http://www.cordblood-america.com ),focused on ... to families,nationwide and internationally, today announced its wholly ... on car #49 at the Sunday, March 2, ...
... For centuries, engineers have bent and torn metals to ... the University of Pennsylvania School of Engineering and Applied ... sizes in the form of wires a thousand times ... Penn engineers to construct a theoretical model to predict ...
Cached Biology Technology:MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results 2MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results 3MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results 4MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results 5MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results 6MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results 7MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results 8MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results 9MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results 10MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results 11MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results 12MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results 13MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results 14MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results 15Cord Blood America Subsidiary Featured at NASCAR Sprint Cup Series Race 2Cord Blood America Subsidiary Featured at NASCAR Sprint Cup Series Race 3Surface dislocation nucleation: Strength is but skin deep at the nanoscale, Penn engineers discover 2
(Date:7/11/2014)... WASH. July 11, 2014 Researchers have ... three-dimensional images. The new technology, called Virtual Finger, ... small structures like neurons and synapses using the ... unique technology makes 3D imaging studies orders of ... at an unprecedented level across many areas of ...
(Date:7/11/2014)... that transplantation of mesenchymal stem cells can stimulate neurogenesis ... of Alzheimer,s disease (AD) and improve tissue and function ... are reported on the therapeutic effect of adipose-derived stem ... the effect on oxidative injury and neurogenesis in the ... team, School of Life Sciences, Tsinghua University, China transplanted ...
(Date:7/11/2014)... under the normal circumstances, astrocytes participate in ... environment, and exhibit therapeutic and repairing effects ... studies have found that nerve cells differentiated ... have reduced viability, which produces influences on ... Kailuan General Hospital, Hebei United University, China ...
Breaking Biology News(10 mins):Virtual finger enables scientists to navigate and analyze complex 3D images 2
... suffer severe burns. The resulting large, deep wounds caused by ... is needed to reduce this kind of scarring is the ... of skin can be removed from the individual patient as ... grafting, another option is to engineer a skin graft in ...
... centres in synthetic biology will be established in ... to funding from the Biotechnology and Biological Sciences ... Sciences Research Council (EPSRC). The 40M+ investment ... and Science David Willetts tonight at a BBSRC ...
... have had bariatric surgery may need to take dietary ... a UT Southwestern Medical Center study suggests. The ... , tracked a group of gastric banding patients and ... most still did not meet recommended daily requirements for ...
Cached Biology News:Blood and lymphatic capillaries grown for the first time in the lab 2UK establishes 3 new synthetic biology research centers 2Gastric banding patients should closely monitor nutrition following surgery 2Gastric banding patients should closely monitor nutrition following surgery 3